Who
Mihael Hristos Polymeropoulos
President and CEO
Company insider
Files Form 4 as: President and CEO, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 320
- Buys
- 17
- Sells
- 54
- Bought
- $986K
- Sold
- $34.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Nov 2006
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.3M156,235 at $8.17 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.3M156,235 at $8.17 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —525,000 at $0.00 | filing |
| 7 Aug 2025filed 8 Aug 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $42K10,000 at $4.15 | filing |
| 21 May 2025filed 21 May 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $42K9,519 at $4.40 | filing |
| 21 May 2025filed 21 May 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $2,112481 at $4.39 | filing |
| 16 May 2025filed 19 May 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $84K20,000 at $4.22 | filing |
| 6 Mar 2025filed 6 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $25K5,000 at $5.02 | filing |
| 6 Mar 2025filed 6 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $25K5,000 at $5.01 | filing |
| 5 Mar 2025filed 5 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $25K5,000 at $5.01 | filing |
| 5 Mar 2025filed 5 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $25K5,000 at $5.03 | filing |
| 3 Mar 2025filed 4 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $47K10,000 at $4.71 | filing |
| 1 Mar 2025filed 4 Mar 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $457K95,999 at $4.76 | filing |
| 28 Feb 2025filed 28 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $48K10,000 at $4.76 | filing |
| 27 Feb 2025filed 27 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $48K10,000 at $4.76 | filing |
| 26 Feb 2025filed 26 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $24K5,000 at $4.75 | filing |
| 26 Feb 2025filed 26 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $24K5,000 at $4.78 | filing |
| 25 Feb 2025filed 25 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Bought | $45K10,000 at $4.46 | filing |
| 18 Feb 2025filed 20 Feb 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Mihael Hristos Polymeropoulos; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.